GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » CareDx Inc (NAS:CDNA) » Definitions » Change In Other Working Capital

CDNA (CareDx) Change In Other Working Capital : $-6.1 Mil (TTM As of Mar. 2025)


View and export this data going back to 2014. Start your Free Trial

What is CareDx Change In Other Working Capital?

CareDx's Change In Other Working Capital for the quarter that ended in Mar. 2025 was $-1.5 Mil. It means CareDx's Other Working Capital declined by $1.5 Mil from Dec. 2024 to Mar. 2025 .

CareDx's Change In Other Working Capital for the fiscal year that ended in Dec. 2024 was $-6.1 Mil. It means CareDx's Other Working Capital declined by $6.1 Mil from Dec. 2023 to Dec. 2024 .

CareDx Change In Other Working Capital Historical Data

The historical data trend for CareDx's Change In Other Working Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CareDx Change In Other Working Capital Chart

CareDx Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Change In Other Working Capital
Get a 7-Day Free Trial Premium Member Only Premium Member Only 18.00 -24.48 -3.67 -4.85 -6.05

CareDx Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Change In Other Working Capital Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.47 -1.50 -1.40 -1.68 -1.48

CareDx Change In Other Working Capital Calculation

Change In Other Working Capital is any increase or decrease between periods of other working capital that are not otherwise classified.

Change In Other Working Capital for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $-6.1 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

CareDx Change In Other Working Capital Related Terms

Thank you for viewing the detailed overview of CareDx's Change In Other Working Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

CareDx Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » CareDx Inc (NAS:CDNA) » Definitions » Change In Other Working Capital
Comparable Companies
OPK NEOG NEO FLGT CSTL PSNL MYGN GRAL XGN MEHCQ TSE:2397 TMO DHR XSWX:LONN IDXX A IQV SHSE:603259 MTD NTRA
Traded in Other Exchanges
1K9:Germany 1K9:Germany
Address
8000 Marina Boulevard, Brisbane, CA, USA, 94005
Website
https://www.caredx.com
CareDx Inc operates as a precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. It offers testing services, products, and digital solutions along with the pre- and post-transplant patient journey and is a provider of genomics-based information for transplant patients. The Company's commercially available testing services consist of AlloSure Kidney, AlloMap Heart, AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. Geographically the company generates the majority of its revenue from the United States. The company generates the majority of revenue from the Testing services.
Executives
Christine Cournoyer director 150 SHAW ROAD, CHESTNUT MA 02467
Peter Maag director, officer: President and CEO CAREDX, INC., 3260 BAYSHORE BOULEVARD, BRISBANE CA 94005
Abhishek Jain officer: See Remarks C/O CAREDX, INC., 1 TOWER PLACE, 9TH FLOOR, SOUTH SAN FRANCISCO CA 94080
George Bickerstaff director C/O VION PHARMACEUTICALS, INC., 4 SCIENCE PARK, NEW HAVEN CT 06511
Alexander L Johnson officer: Chief Business Officer C/O DIADEXUS, INC., 349 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO CA 94080
Reginald Seeto officer: See Remarks C/O ARDELYX, INC., 34175 ARDENWOOD BLVD, SUITE 200, FREMONT CA 94555
Abraham Ronai officer: See Remarks C/O CAREDX, INC., 8000 MARINA BLVD, BRISBANE CA 94005
Grace Colon director C/O CAREDX, INC., 3260 BAYSHORE BOULEVARD, BRISBANE CA 94005
Michael Goldberg director 3000 SAND HILL ROAD, BUILDING 3, SUITE 290, MENLO PARK CA 94025
Ankur Dhingra officer: Chief Financial Officer C/O CAREDX, INC., 1 TOWER PLACE, 9TH FLOOR, SOUTH SAN FRANCISCO CA 94080
Arthur A Torres director 87 BVENA VISTA TERRACE, SAN FRANCISCO CA 94117
Hannah Valantine director 1305 O'BRIEN DRIVE, MENLO PARK CA 94025
Sasha King officer: Chief Commercial Officer C/O CAREDX, INC., 3260 BAYSHORE BOULEVARD, BRISBANE CA 94005
William A Hagstrom director 320 WAKARA WAY, SALT LAKE CITY UT 84108
Ralph Snyderman director C/O SAIC, 10260 CAMPUS POINT DR M/S F3, SAN DIEGO CA 92121